Implementation study of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research
Authors' conclusion
Both the MTX and TNFi uveitis CTPs can practically be implemented in clinical settings and are currently being utilized across Registry sites.
Study context
- Population
- Patients with JIA-associated chronic anterior uveitis (CAU) (JIA-U) at nine CARRA pilot sites, February 2020 to August 2022pilot cohort
- Participants
- 17 patients
- Exposure
- Methotrexate (MTX) CTP vs TNF inhibitor (TNFi) CTP
- MTX CTPn = 8
- TNFi CTPn = 9
- Outcome
- Uveitis control
- Follow-up
- 6 months
Methodological detailsimplementation study, multicentre (nine pilot sites), Uveitis activity and medication use recorded at 0, 3 and 6 months
- Implementation study
- Multicentre (nine pilot sites)
- Uveitis activity and medication use recorded at 0, 3 and 6 months
Main finding
As reported in the abstract
Uveitis controlled in pilot cohort
13 of 17
TNFi CTP: none selected high-dose adalimumab or infliximab
0
Observational data: associations, not effects.
Further findings
| Outcome | MTX CTP | TNFi CTP |
|---|---|---|
| CTP arm selection in CARRA Registry retrospective cohort (n = 42) | ||
| Oral | 8 | — not stated in the abstract |
| Subcutaneous | 18 | — not stated in the abstract |
| Standard dose adalimumab | — not stated in the abstract | 12 |
| High dose adalimumab | — not stated in the abstract | 2 |
| Infliximab | — not stated in the abstract | 2 |
— not stated in the abstract
Original publication
Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatr Rheumatol Online J. Published 7 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →